Drug Profile
Adalimumab biosimilar - Pfizer
Alternative Names: ABRILADA; Adalimumab-afzb; Amsparity; PF-06410293Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
Most Recent Events
- 10 Nov 2022 Efficacy and adverse events data from a phase III trial in Rheumatoid arthritis presented at the ACR Convergence 2022
- 25 Feb 2022 FDA assigns the Biosimilar User Fee Act (BsUFA) goal date of Q4 2022 for Adalimumab biosimilar for Rheumatoid arthritis
- 25 Feb 2022 The US FDA accepts for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab)